Related Experiment Video
Updated: Jul 13, 2026
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis
1Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai, China.
Insights
Heparin is safe for ulcerative colitis patients but offers no additional benefit over standard treatments. This meta-analysis found no significant additive effect in clinical trials.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Trials
Background:
- Ulcerative colitis treatment has been explored with heparin, yielding inconsistent results across various studies.
- Heparin's role as a supplemental therapy warrants further investigation due to varied outcomes in prior trials.
Purpose of the Study:
- To assess the efficacy and safety of heparin as an add-on treatment for ulcerative colitis.
- To compare heparin supplementation against conventional therapy in ulcerative colitis patients.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted.
- Electronic databases were searched to identify relevant studies comparing heparin supplementation with conventional therapy.
- Statistical analyses, including sub-analysis and sensitivity analysis, were performed using Review Manager 4.2.8.
Main Results:
- Eight RCTs involving 454 participants were analyzed.
- Heparin supplementation showed an overall odds ratio (OR) of 0.78 (95% CI = 0.50-1.21) for efficacy compared to conventional therapy.
- Unfractionated heparin demonstrated a significant OR of 0.26 (95% CI = 0.07-0.93), while low-molecular-weight heparin showed an OR of 0.92 (95% CI = 0.57-1.47).
- Few serious adverse events were reported, indicating a favorable safety profile.
Conclusions:
- Heparin administration appears safe for patients with ulcerative colitis.
- The current meta-analysis does not support an additive therapeutic benefit of heparin over conventional treatments for ulcerative colitis.
Background:
The use of heparin for the treatment of ulcerative colitis has been evaluated in several open and controlled trials, with varying outcomes.
Aim:
To evaluate the efficacy and safety of heparin as supplemental therapy compared with conventional therapy in patients with ulcerative colitis.
Methods:
All randomized trials comparing heparin supplementation to conventional therapy were included from electronic databases. Statistical analysis was performed with review manager 4.2.8 (The Cochrane Collaboration, Oxford, UK). Sub-analysis and sensitivity analysis were also performed.
Results:
Eight randomized-controlled trials, investigating a total of 454 participants, met the inclusion criteria. The odds ratio (OR) for the efficacy of heparin supplementation vs. conventional therapy was 0.78 (95% CI = 0.50-1.21). Few serious adverse events were observed. The OR for the efficacy of unfractionated heparin and low-molecular-weight heparin vs. conventional therapy was 0.26 (95% CI = 0.07-0.93) and 0.92 (95% CI = 0.57-1.47), respectively. The OR for the efficacy of heparin vs. conventional therapy with placebo was 0.87 (95% CI = 0.53-1.44).
Conclusions:
Our meta-analysis suggests that administration of heparin in patients with ulcerative colitis is safe, but no additive benefit over conventional therapy is indicated.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:29Venous Thrombosis III: Interprofessional Care
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...